Browsing by Author "Kátia Sanches Françoso"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP119
    (2017-04-25) Mariana Vilela Rocha; Kátia Sanches Françoso; Luciana Chagas Lima; Tarsila Mendes Camargo; Ricardo L.D. Machado; Fabio T.M. Costa; Laurent Rénia; Francois Nosten; Bruce Russell; Mauricio M. Rodrigues; Irene S. Soares; Universidade de Sao Paulo - USP; Instituto Evandro Chagas; Universidade Estadual de Campinas; A-Star, Singapore Immunology Network; Mahidol University; Nuffield Department of Clinical Medicine; University of Otago; Universidade Federal de Sao Paulo
    © 2017 Elsevier Ltd Plasmodium vivax is the most widely distributed malaria species and the most prevalent species of malaria in America and Asia. Vaccine development against P. vivax is considered a priority in the global program for the eradication of malaria. Earlier studies have characterized the Apical Membrane Antigen 1 (AMA-1) ectodomain and the C-terminal region (19 kDa) of the Merozoite Surface Protein 1 (MSP-1) of P. vivax as immunodominant antigens. Based on this characterization, we designed a chimeric recombinant protein containing both merozoite immunodominant domains (PvAMA166-MSP119). The recombinant PvAMA166-MSP119 was successfully expressed in Pichia pastoris and used to immunize two different mouse strains (BALB/c and C57BL/6) in the presence of the Poly (I:C) as an adjuvant. Immunization with the chimeric protein induced high antibody titers against both proteins in both strains of mice as detected by ELISA. Antisera also recognized the native proteins expressed on the merozoites of mature P. vivax schizonts. Moreover, this antigen was able to induce IFN-gamma-secreting cells in C57BL/6 mice. These findings indicate that this novel yeast recombinant protein containing PvAMA166 and PvMSP119 is advantageous, because of improved antibody titers and cellular immune response. Therefore, this formulation should be further developed for pre-clinical trials in non-human primates as a potential candidate for a P. vivax vaccine.
  • No Thumbnail Available
    PublicationMetadata only
    Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge
    (2018-12-01) Tarsila Mendes De Camargo; Elisângela Oliveira De Freitas; Alba Marina Gimenez; Luciana Chagas Lima; Karina De Almeida Caramico; Kátia Sanches Françoso; Oscar Bruna-Romero; Chiara Andolina; François Nosten; Laurent Rénia; Hildegund C.J. Ertl; Ruth S. Nussenzweig; Victor Nussenzweig; Mauricio M. Rodrigues; Arturo Reyes-Sandoval; Irene S. Soares; A-Star, Singapore Immunology Network; NYU School of Medicine; Universidade Federal de Santa Catarina; Universidade Federal de Sao Paulo; Mahidol University; The Wistar Institute; Nuffield Department of Clinical Medicine; Universidade de Sao Paulo - USP
    © 2018 The Author(s). Vaccine development against Plasmodium vivax malaria lags behind that for Plasmodium falciparum. To narrow this gap, we administered recombinant antigens based on P. vivax circumsporozoite protein (CSP) to mice. We expressed in Pichia pastoris two chimeric proteins by merging the three central repeat regions of different CSP alleles (VK210, VK247, and P. vivax-like). The first construct (yPvCSP-AllFL) contained the fused repeat regions flanked by N- and C-terminal regions. The second construct (yPvCSP-AllCT) contained the fused repeat regions and the C-terminal domain, plus RI region. Mice were vaccinated with three doses of yPvCSP in adjuvants Poly (I:C) or Montanide ISA720. We also used replication-defective adenovirus vectors expressing CSP of human serotype 5 (AdHu5) and chimpanzee serotype 68 (AdC68) for priming mice which were subsequently boosted twice with yPvCSP proteins in Poly (I:C) adjuvant. Regardless of the regime used, immunized mice generated high IgG titres specific to all CSP alleles. After challenge with P. berghei ANKA transgenic parasites expressing Pb/PvVK210 or Pb/PvVK247 sporozoites, significant time delays for parasitemia were observed in all vaccinated mice. These vaccine formulations should be clinically tried for their potential as protective universal vaccine against P. vivax malaria.